論文・技術情報追加のお知らせ

1. Comparison of safety profiles for dapagliflozin based on EMA and FDA safety issues: Challenges and future of post-marketing surveillance in Korea.

韓国の薬剤監視システム、欧米と比較した安全性評価

対象DB：FAERS,KAERS

2. A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases.

IDH阻害薬の副作用比較、患者に応じた治療が必要

対象DB：FAERS

3. Disproportionality analysis of oesophageal toxicity associated with oral bisphosphonates using the FAERS database (2004-2023).

経口ビスホスホネートが食道毒性と関連

対象DB：FAERS

4. Country-specific psychopharmacological risk of reporting suicidality comparing 38 antidepressants and lithium from the FDA Adverse Event Reporting System, 2017-2023.

抗うつ薬の黒枠警告は若年層に有効、国による差あり

対象DB：FAERS

5. Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database.

メポリズマブの副作用には呼吸器・免疫系障害が多い

対象DB：FAERS

6. Comprehensive Analysis of Mitotane-Related Adverse Events Using the FDA Adverse Event Reporting System.

ミトタネの副作用には既知・未知の反応がある

対象DB：FAERS

7. Adverse event reporting of combining SGLT2 inhibitor and GLP1 receptor agonist: A real-world study from FAERS.

SGLT2iとGLP1RA併用で有害事象は増加しない

対象DB：FAERS

8. KRAS-G12 inhibitors in lung cancer therapy: unveiling the toxicity profile through a pharmacovigilance study.

KRAS G12C阻害剤は消化器症状や腎肝障害を引き起こす

対象DB：FAERS

9. Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups.

ティルゼパチドの副作用は消化器障害が多い

対象DB：FAERS

10. Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy.

CAR-T療法後の急性腎障害が予後に影響

対象DB：FAERS

11. Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA adverse event reporting system.

アズトレオナムに関連する新たな副作用シグナルを特定

対象DB：FAERS

12. Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system.

オシメルチニブが再生不良性貧血を引き起こす可能性

対象DB：FAERS

13. Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database.

ファムシクロビルの潜在的副作用を特定

対象DB：FAERS

14. Comparative Post-Marketing Surveillance of Memantine and Cholinesterase Inhibitors: Cardiovascular Adverse Events With a Focus on Sex Differences Using the FDA Adverse Event Reporting System Database.

メマンチンと抗認知症薬で心血管障害に性差あり

対象DB：FAERS

15. Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist.

FGFR阻害剤で高リン血症が多発、対策強化が必要

対象DB：FAERS

16. Unveiling the Hidden Risks: An Update Decade-Long Analysis of Abraxane-Related Adverse Events from the FAERS Database.

アブラキサンは血液障害や神経障害など副作用が多い

対象DB：FAERS

17. Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.

ベリムマブはうつ症状や蛋白尿などの副作用が多い

対象DB：FAERS

18. Real-World Pharmacovigilance Study Identifies Drugs Linked to Hepatitis B Virus Reactivation.

HBVrを引き起こす薬剤は抗がん剤や免疫調整薬が多い

対象DB：FAERS,JADER

19. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag.

アバトロンボパグの副作用として血栓や頭痛などが確認された

対象DB：FAERS

20. Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system.

GLP-1受容体作動薬は骨折関連副作用が少ない

対象DB：FAERS

21. Comparison of Adverse Event Profiles of Amphotericin B Formulations Using Real-World Data.

アンフォテリシンBとリポソーム製剤の副作用プロファイル比較

対象DB：FAERS

22. Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.

GLP-1受容体作動薬で過剰投薬のリスク増加

対象DB：FAERS

23. Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024.

抗癌薬などが引き起こす薬剤性膀胱炎のリスク

対象DB：FAERS

24. Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety.

クロザピンは感染症や心筋炎など致命的な副作用を伴う

対象DB：VigiBase

25. Clinical outcomes of endovascular interventions for cerebral venous thrombosis in Japan: a nationwide retrospective study.

静脈血栓症に対する血管内治療の効果は限定的

対象DB：DPC

26. Association between warfarin use and thromboembolic events in patients post-Fontan operation: propensity-score overlap weighting analyses.

フォンタン手術後のワルファリン使用と血栓塞栓症の関連調査

対象DB：DPC

27. Characteristics and outcomes of patients with postpartum hemorrhage undergoing transcatheter arterial embolization: A nationwide observational study.

産後出血患者の動脈塞栓術後の転帰と特徴分析

対象DB：DPC

28. The estimation of healthcare cost of kidney transplantation in Japan using large-scale administrative databases.

日本における腎移植の医療費推計

対象DB：JMDC

29. Contemporary Use of beta-Blockers in Heart Failure Patients With and Without Atrial Fibrillation: A Nationwide Database Analysis.

心不全患者でβ遮断薬使用は予後改善に関連

対象DB：NDB

30. Investigation of Severe Hypoglycemia Risk Among Patients with Diabetes Treated with Ultra-Rapid Lispro in Japan.

URLi使用患者で重度低血糖のリスクに有意差なし

対象DB：MDV

31. Antidepressant use during pregnancy and birth outcomes: analysis of electronic health data from the UK, Norway, and Sweden.

妊娠中の抗うつ薬使用は早産や死産リスク増加

対象DB：CPRD

32. Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged >/=55 years: nested case-control study.

抗コリン薬の一部は認知症リスク増加と関連

対象DB：CPRD

33. Association of intra-articular injection and knee arthroscopy prior to primary knee replacement with the timing and outcomes of surgery: Retrospective cohort study using data from the Clinical Practice Research Datalink GOLD database.

ステロイド注射と関節鏡は膝置換術後の予後を悪化させる

対象DB：CPRD

34. Oral Corticosteroid-Related Healthcare Resource Utilization and Associated Costs in Patients with COPD.

COPD患者でOCS使用は医療利用・費用増加と関連

対象DB：CPRD

35. Antidiabetic Medication and Asthma Attacks.

メトホルミンは喘息発作を減少、GLP-1RAでさらに効果

対象DB：CPRD

36. Immune checkpoint inhibitor-related type 1 diabetes incidence, risk, and survival association.

ICI-T1DMは発症率0.48%、生存率向上に関連

対象DB：DeSC

37. Adding biomarker change information to the kidney failure risk equation improves predictive ability for dialysis dependency in eGFR

KFREモデルに年次変化を追加で透析予測精度向上

対象DB：DeSC